Opinion|Videos|January 9, 2024
Identifying the Right CDMO to Support Biopharma Manufacturing
Author(s)Ascendia Pharma
Robert Bloder, Chief Business Officer, Ascendia Pharmaceuticals, highlights traits that a (bio)pharmaceutical company look for when identifying a CDMO to support drug development and manufacturing programs.
Robert Bloder, Chief Business Officer, Ascendia Pharmaceuticals discusses:
- What to look for when identifying a CDMO for a drug development project
- Ascendia Pharmaceuticals and its expansion of manufacturing services
- Ascendia Pharmaceuticals as a "Partner of Choice"
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
Women in STEM: Early Phase Drug Development
2
Drug Digest: Outsourcing Partnerships Fuel Global Biopharma Discovery and Scale-Up
3
FDA Grants Priority Review For Pfizer’s Marstacimab for Hemophilia A or B
4
PharmTech Weekly Roundup - February 6, 2026
5